The structural prerequisites for lipopolysaccharide (LPS) and its partial structures for the activation of the Limulus clotting cascade (Limulus amebocyte lysate [LAL] test) are described and compared with the corresponding requirements for the activation of human immune cells such as mononuclear cells. A necessary, but not sufficient, structural motif for this is the presence of the 4 0 -phosphate-diglucosamine backbone recognition structure ('epitope') in lipid A. High activity is only expressed by assemblies of endotoxins, but this is largely independent of the type of supramolecular aggregate structure. A particular conformation of the epitope within the lipid A assembly must be present, which is influenced by addition of further saccharide units to the lipid A moiety, but also reacts slightly to the acylation pattern. In contrast, the cytokine production of human immune cells induced by LPS sensitively depends on the type of its aggregate structure. In the case of a hexa-acylated bisphosphorylated lipid A structure, high activity is only observed with cubic inverted aggregates. Furthermore, addition of antimicrobial agents (such as polymyxin B) leads to a nearly complete inhibition of cytokine production, whereas the reduction in the Limulus assay is much lower. These data are important since a reliable determination of endotoxin concentrations, in particular with respect to its ability to elicit severe infections, is of high interest.
INTRODUCTION
Lipopolysaccharides (LPSs) belong to the most potent elicitors of the mammalian immune system due to the induction of a series of cytokines such as tumornecrosis-factor-a (TNF-a) in immunocompetent cells like mononuclear cells. 1 The effects of LPS on human health may be beneficial at low concentrations to combat infectious diseases, but becomes pathological at too high a concentration leading to the severe septic shock syndrome with multi-organ failure and death, with cases numbering in the range of millions world-wide. 2 It is, therefore, of utmost importance to have a reliable method for measuring the concentrations of endotoxins, for example in human body fluids.
For many years, activation of the clotting cascade from the horseshoe crab (Limulus polyphemus), Limulus amebocyte lysate (LAL), originally developed by Levin and co-workers, [3] [4] [5] [6] has been the standard and most sensitive assay to detect bacterial endotoxins. There are, however, also some limitations with this test. In a prospective study of an AMCC (Academic Medical Center Consortium) sepsis project working group, it was found that the results from the LAL test did not correlate with the presence of bacteremia due to Gram-negative organisms nor with mortality, but rather correlated with the presence of fungal bloodstream infection. 7 This resulted from the fact that the LAL assay does not only respond to bacterial endotoxins but is also activated by the presence of b-(1!3)-linked D-glucan, a type of polysaccharide commonly present in fungi. 8 (However, commercial kits are available which avoid such activation). In previous reports, the clotting cascade was found to consist of three serine protease zymogens (factors C and B and proclotting enzyme). 9 The main factor sensitive to LPS is factor C, which was shown to react rapidly to lipid A structures such as synthetic tetra-acyl (406) and hexa-acyl (506) lipid A. 10 The structural requirements for activation of the LAL test with various synthetic lipid A part structures were analysed in several studies: LAL activity correlated with progenicity but not with activation of the complement cascade, 11 and the comparison of in vitro and in vivo activities showed large variations in the different test systems. 10 In particular, the presence of phosphates at both the 1-and 4 0 -position (compound LA-15-PP or 506) gave highest activity, whereas the absence of one group (compounds LA-15PH ¼ 505 and LA-15-HP ¼ 504) reduced the activity. In the LAL test compounds 506 and 504 corresponding to bisphosphoryl and 4 0 -monophosphoryl lipid A, respectively, were, however, nearly equally active, whereas 1-monophosphoryl lipid A was less active by one to two orders of magnitude. Furthermore, it was found that underacylated (tetraand penta-acyl) lipid A exhibited high Limulus activity (unpublished observations) whereas they were either inactive or only weakly active, respectively, in the cytokine test. 12 Additionally, it was recently shown that the cytokine production induced by LPS from different species in the whole blood assay did not always correlate with the response from the LAL test. 13 Experimental evidence also indicated that a particular recognition structure in the lipid A part of LPS, the 4 0 -monophosphoryldiglucosamine backbone, must be present for activation of the Limulus clotting cascade.
14 Independently of these details, the endotoxin must be in an aggregated form for cytokine induction as well as for activation in the LAL test. 15 To clarify the questions raised by the different experimental findings, a systematic study of the structural prerequisites was performed using a variety of LPSs as well as synthetic and natural lipid A analogues and partial structures. This allowed us to assign, in detail, the conformation of the recognition structure necessary for activation of the Limulus clotting cascade, and thus to determine where the LAL assay concurs or not with the whole blood assay of cytokine production.
MATERIALS AND METHODS

Synthetic compounds
The used synthetic hexa-acyl lipid A compounds 506, CM-506, and tetra-acyl lipid A 406, carboxymethylated Bis-CM-506 and Bis-CM-406 as well as monophosphoryl compounds 504 (4 0 -phosphate) and 505 (1-phosphate) and Kdo-505 and Kdo-506 have been described previously. [16] [17] [18] [19] [20] [21] The chemical structures of various lipid A analogues are presented in Figure 1 .
Lipids and reagents
Lipopolysaccharides from the rough mutants Re and Ra from Salmonella enterica sv. Minnesota R595 and R60, respectively, deep rough mutant from Proteus mirabilis R45, and LPS from Yersinia pestis grown at 26 C and 37 C were extracted by the phenol/chloroform/light petroleum method 22 from bacteria, purified, and lyophilized.
Lipid A was isolated from R595 LPS by mild acetate treatment and purified as described earlier. 23 A pentaacyl lipid A was isolated from a mutant of Escherichia coli strain F515, which produces quantitatively only LPS with five acyl chains.
The lipid A headgroup (tetrasaccharide bisphosphate TSP 2 ) was isolated from LPS (E. coli F515) after strong alkaline treatment (4 M KOH, 100 C, 5 h) and purification of the oligosaccharides by high-performance anionexchange chromatography (HPAEC) as described elsewhere.
23,24
Determination of cytokine induction
Mononuclear cells (MNCs) were isolated from peripheral blood taken from healthy donors by the HypaqueFicoll density gradient method. The cell number was equilibrated at 5 Â 10 6 cells/ml RPMI 1640 containing 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. For stimulation, 200 ml/well MNCs were transferred into 96-well culture plates. The stimuli were serially diluted in RPMI 1640 and added to the cultures at 20 ml per well. The cultures were incubated for 4 h at 37 C under 5% CO 2 . Cell-free supernatants were collected after centrifugation of the culture plates for 10 min at 400 g and stored at À20 C until determination of the cytokine content. Immunological determination of TNF-a in the cell supernatant was performed in a sandwich-ELISA as described earlier.
14 Tumor necrosis factor-a was determined in duplicate at two different dilutions and the values were averaged.
Determination of endotoxin activity by the chromogenic Limulus test
Endotoxin activity of LPS and the lipid A analogs and part structures was determined by a quantitative kinetic assay based on the reactivity of Gram-negative endotoxin with Limulus amebocyte lysate (LAL) at 37 C, using test kits of LAL Coamatic Chromo-LAL K (Chromogenix, Haemochrom). 25 The standard endotoxin used in this test was from E. coli (O55:B5) and 10-15 endotoxin units (EU)/ml correspond to 1 ng/ml. In this assay, saturation occurs at 50 EU/ml, and the resolution limit is 40.05 EU/ml (maximum value for ultrapure water, Aqua B. Braun).
RESULTS AND DISCUSSION
The extreme sensitivity of the Limulus test in detecting bacterial endotoxins is presented in Figure 2A ,B showing activity down to 10 pg/ml (0.01 ng/ml) at least for Re LPS from S. enterica sv. Minnesota (strain R595). Lipopolysaccharide from P. mirabilis strain Re45 with a non-stoichiometrically bound 4-amino4-deoxy-L-arabinose linked to the 4 0 -phosphate 26 is significantly less active than R595 LPS (see values at 1 ng/ml and 0.1 ng/ml LPS). Lipopolysaccharide from Chromobacterium violaceum with a 3/3 configuration 12 (three acyl chains are bound to the reducing and non-reducing part, respectively, of the diglucosamine) has nearly the same activity as LPS R595 except at the lowest concentrations; however, lipid A extracted from R595 LPS has clearly a reduced activity.
The activity of LPS from Y. pestis grown at 26 C and 37 C, respectively, was compared. These strains differ in lipid A chemical structure, with the strain grown at 26 C having a significant amount of a hexa-acylated species, which is not found in the 37 C sample. 27 The data of Figure 2B show a slightly higher activity of the LPS from the 37 C strain, but both samples have a reduced activity when compared to Re LPS from Salmonella. In contrast, the data from tests of the cytokine production in mononuclear cells show significant activity for LPS from the 26 C strain, but not for that grown at 37 C. 24 To test the influence of particular functional groups, different fragments of lipid A were investigated. In a first step, pure backbone structures were analysed, i.e. diglucosamine, Kdo 2 -(GlcN) 2 -1-P (TSP 1 ) and Kdo 2 -(GlcN) 2 -1,4 0 -P 2 (TSP 2 ). The data in Figure 3 show that the pure sugar and TSP 1 do not exhibit any activity, in contrast to the compound with the 4 0 -phosphate. This means that the 4 0 -phosphate in combination with the diglucosamine is the minimal structure for expression of LAL activity. Comparison with the values in Figure 2 indicates, however, that acyl chains are necessary for full expression of activity. It can be interpreted that the low activity of the pure backbone structures is due to the fact that they do not form aggregates. In a second step, synthetic lipid A analogues were analysed (see Fig. 1 The data in Table 1 prove high activity for compound 406, followed by 506. Compound CM-506 still has high activity, whereas compounds lacking phosphates exhibit reduced activity, but are not inactive. Interestingly, the samples 505 and Kdo-505 which have no 4 0 -phosphate are nearly inactive.
The data in Table 1 give clear evidence that the acylation pattern for compounds with a diglucosamine-4 0 -phosphate backbone only marginally influences LAL activity, i.e. compounds 406, 506, Kdo-506, 504, and triacyl lipid A have comparable activity. These compounds may differ in their aggregate structures (taken from the literature 12,28,29 and unpublished observations). The aggregate structures vary from lamellar (L) over mixed cubic-lamellar (Q/L) and pure cubic (Q) to micellar (M) ones (data from the literature 28, 29 ). Clearly, the type of aggregate structure only marginally, if at all, influences the reactivity in the Limulus test. The data show, furthermore, that the existence of a diglucosamine is a necessary feature for activation. Indeed, analysis of the monosaccharide part structures GLA-58 and GLA-69 corresponding to the non-reducing part of lipid A gives very low activity, when one of the glucosamine monosaccharides is missing. The data for tri-acyl lipid A with both phosphates indicate that three acyl chains are sufficient to provide nearly full activity (Table 1) . When comparing these values with those from the acyl chain-free compounds (Fig. 3) , it becomes clear, however, that acyl chains are required for high LAL activity.
A comparison of the LAL data with published results from the cytokine expression in mononuclear cells induced by these compounds (right column in Table 1 , see the literature 30, 31 ) gives clear evidence that, in the human immune cell system, the aggregate structure of LPS is the decisive feature: only compounds adopting cubic inverted structures are highly active. Differences in cytokine expression of compounds with cubic structures result from differences in acyl chain mobility as outlined earlier. 32 The differences observed in the two biological test systems is in accordance with the results of Dehus et al., 13 who found that the whole blood assay 'does not always correlate' with the Limulus test for the immune stimulatory potency of 11 different LPS samples from entero-as well as non-enterobacterial origin; for example, the comparison of LPS from Pseudomonas aeruginosa with that from S. enterica sv. Abortus equi showed an overestimation of the pyrogenic burden by a 
factor of 500 in the LAL test when compared with the cell assay. The interaction between LPS and the purified factor C from Tachypleus tridentatus studied by Nakamura et al. 33 showed that the detergent Triton-X, which destroys LPS aggregates, inhibited the LPS-mediated binding of factor C. This gives clear evidence that the aggregated form of LPS is responsible for binding to factor C, and this is what has been found explicitly in previous reports, in which the comparison of monomeric and aggregated forms of lipid A and LPS exhibited a high activity for the latter but no activity in the former administration. 15 Since the LAL assay is frequently used to test the effectiveness of antimicrobial drugs for the neutralization of LPS, the action of the 'gold standard' polymyxin B (PMB) on the response in the Limulus test was also monitored (Fig. 5) and compared with the respective results in the cell assay (Fig. 4) . The data in Figure 4 show that a significant reduction of the LAL activity is observed only at the lowest concentration of Ra LPS (1 ng/ml), both at an excess of 10:1 and 100:1 weight percent PMB:LPS. In contrast, the results from the cytokine expression in human mononuclear cells exhibit high inhibition values at all LPS concentrations and both LPS:PMB ratios. Similar data were obtained also for LPS Re45, a deep rough mutant LPS from the PMBresistant strain P. mirabilis R45, and for free lipid A from S. enterica sv. Minnesota R595 LPS. The cell assay data give clear evidence that PMB reduces cytokine expression similar to that found for Ra LPS (data not shown). In contrast, the LAL reactivity, although reduced, still shows considerable response (Fig. 6) .
It has been shown that the aggregate structures of lipid A or LPS convert in the presence of antimicrobial agents such as PMB from a cubic or mixed cubic/unilamellar form into a multilamellar organisation. 34, 35 Therefore, as described above for the compounds which are a priori inactive (e.g. compound 406), the existence of the multilamellar aggregate form is a necessary prerequisite for endotoxin inactivity/inactivation in producing cytokines. 25, 36 The clotting cascade consists of three serine protease zymogens (factors C and B and proclotting enzyme). 9 The recognition structure within the Limulus clotting cascade, factor C, can bind to the 4 0 -phosphate-diglucosamine part of lipid A/LPS also in the presence of added antimicrobial agents. This LPS-sensitive serine-protease was found to be a novel type of serine proteases 37 and, as initiator of the hemolymph coagulation system after binding to LPS, is expressed in a nearly identical form in the American horseshoe crab Limulus polyphemus as in the east Asian crab Tachypleus tridentatus. 38 Factor C with a molecular mass (MM) of 123,000 g/mol, consisting of a light chain (MM ¼ 43000 g/mol) and a heavy chain (MM ¼ 80000 g/mol), is converted into an activated form in the presence of LPS. 33 It associates with LPS on the hemocyte surface which is induced by the binding of a cysteine-rich region to LPS. Upon activation, the light chain is cleaved which leads to accumulation of two new fragments. Factor C* then activates factor B to B*, which in turn converts the proclotting enzyme to the clotting enzyme. In a final step, the clotting enzyme coagulogen, a soluble protein, is converted into an insoluble coagulin gel. In accordance with our data, Nakamura et al. 38 found that the zymogen factor C is rapidly activated by an acylated b-(1!6)-linked D-glucosamine disaccharide bisphosphate, and the corresponding 4 0 -monophosphate; for this, they used tetra-and hexa-acylated lipid A analogs with variations in the phosphate substitution 403 to 406 and 503 to 506, respectively. Their observation that compounds having only the 1-phosphate diglucosamine backbone (405 and 505, respectively) are much less potent in activating factor C is in agreement with our data (Table 1) . They reported, furthermore, that the tetraacylated compounds were more active than the hexaacylated compounds to activate factor C, which corresponds to our results in the comparison of 406 and 506. The comparison of compound 506 and Kdo-506 (Table 1) as well as of the two Yersinia-LPSs (Fig. 2B) indicates that the acylation pattern alone is not sufficient to explain differences in activity. The presence of the Kdo moiety and further sugars apparently leads to a more favorable conformation of the lipid A backbone thus enhancing the accessibility for factor C. This is also clear when comparing Re LPS and lipid A derived from it, indicating a higher activity of the former (Fig. 2A) . It is also noteworthy that the additional substitution with an amino-arabinose at the 4 0 -phosphate for LPS Re45 reduces the activity without inhibiting it ( Fig. 2A) .
CONCLUSIONS
It is clear that the diglucosamine-4
0 phosphate is the decisive epitope in the LAL test. The absent or strongly reduced (Fig. 3 ) activity in the monomeric state indicates that aggregates of the endotoxins are required. The type of aggregate structure is, however, not a determinant of Limulus activity. It remains a task for the future to study the precise molecular conformation of lipid A within LPS aggregates necessary to stimulate factor C.
The prerequisites for the activation of immune cells by endotoxins are different from those for activation of the LAL cascade: In this case, endotoxin aggregates with a suitable endotoxin conformation where the lipid A part adopts a conical wedge-shaped conformation with a smaller cross-section of the backbone compared to that of the hydrophobic part, interact with binding proteins such as lipopolysaccharide-binding protein and CD14. This leads to intercalation of the endotoxins into the target cell membranes, where the endotoxins form domains which strongly disturb the membrane architecture leading to cell activation at the site of transmembrane proteins such as the TLR4/MD2 system. Our data are of utmost interest with respect to the use of the LAL test in monitoring the success of an antimicrobial therapy in patients. As the data show, the Limulus test may indicate false negative values, although LPS-induced cytokine production is considerably inhibited. This means that the LAL test is not necessarily a reliable assay in therapeutic agents. 
